Fortin, Anny
Verbeeck, Roger-K.
[UCL]
Jansen, Frans H.
OBJECTIVE:
The aim of the present study was to compare the pharmacokinetic properties, bioavailability and tolerability of artesunate (AS) and amodiaquine (AQ) administered as a fixed-dose combination (Amonate FDC tablets; Dafra Pharma, Turnhout, Belgium) or as a non-fixed dose combination of separate AS tablets (Arsuamoon; Guilin Pharmaceutical Co, Shanghai, China) and AQ tablets (Flavoquine; Sanofi-Aventis, Paris, France).
METHODS:
This was a randomized, open label, two-period, two-treatment, two-sequence, cross-over study in which 60 healthy male Indian volunteers were given a single total oral dose of 100 mg AS and 400 mg AQ hydrochloride either as two tablets of Amonate FDC (AS 50 mg and AQ hydrochloride 200 mg) or as two AS tablets of the co-blister Arsuamoon (50 mg AS) together with two Flavoquine tablets (200 mg AQ hydrochloride). Plasma AS and blood AQ concentrations, as well as those of their respective active metabolites dihydroartemisinin (DHA) and desethylamodiaquine (DEAQ), were measured by high-performance liquid chromatography-tandem spectrometry. The pharmacokinetic parameters of AS, DHA, AQ and DEAQ were determined by non-compartmental analysis. Bioequivalence assessment was performed by analysis of variance (ANOVA), and calculation of the 90% confidence intervals of the geometric mean ratio test (fixed)/reference (non-fixed) for AUC(0-t) and C(max) for AS, AQ, DHA and DEAQ.
RESULTS:
Interim analysis showed that both treatments were not bioequivalent; therefore, statistical analysis was carried out on the results of all subjects for whom blood/plasma concentrations were available for all four analytes (n=26). The C(max) (maximum plasma/blood concentration) of AS was 67.0 ± 37.1 and 154.8 ± 116.2 ng/mL for the fixed-dose and non-fixed dose administration, respectively. The AUC(0-t) (area under the plasma concentration-time curve from time zero to the last measurable concentration) of AS was 60.1 ± 27.5 and 81.8 ± 44.3 ng h/mL for the fixed-dose and non-fixed dose administration, respectively. The 90% confidence intervals for C(max) and AUC(0-t) of AS were outside the 80-125% acceptance range: 37.02-61.62% and 70.10-83.47%, respectively. The C(max) of AQ was 33.8 ± 13.6 and 31.4 ± 14.1 ng/mL for the fixed-dose and non-fixed dose administration, respectively. The AUC(0-t) of AQ was 332.3 ± 116.6 and 329.8 ± 99.5 ng h/mL for the fixed and non-fixed dose administration, respectively. For AQ, the 90% CIs for C(max) and AUC(0-t) were within the 80-125% acceptance range: 99.17-121.71 and 89.53-107.35%, respectively. Bioequivalence assessment based on the active metabolite data supported the bioequivalence conclusions based on the parent compound data. Both the fixed-dose and non-fixed dose administration of 100 mg AS and 400 mg AQ were well tolerated.
CONCLUSION:
Bioequivalence of the fixed-dose AS/AQ formulation with the non-fixed dose combination of the same drugs was not demonstrated for AS, but it was shown for AQ for both C(max) and AUC(0-t). The results obtained on the active metabolites support this conclusion. Overall, the fixed-dose 50 mg AS/200 mg AQ tablets were not technically bioequivalent with 50 mg AS tablets and 200 mg AQ tablets administered separately. The difference cannot be explained by the pharmaceutical properties of the tablets and seems to be biologically related.
- World Health Organization (2002) WHO urges countries to act on new anti-resistance malaria medicines. Press Release WHO/31. Available at: http://rbm.who.int/amd2002/who_pr31_e.htm . Accessed 12 Jan 2010
- World Heath Organization (2006) WHO calls for an immediate halt to provision of single-drug artemisinin malaria pills. New malaria treatment guideline issued by WHO. News Release WHO. Available at: http://www.who.int/mediacentre/news/releases/2006/pr02/en/ . Accessed: 12 Jan 2010
- Batty Kevin T., Ilett Kenneth F., Davis M. E., Timothy, Chemical Stability of Artesunate Injection and Proposal for its Administration by Intravenous Infusion, 10.1111/j.2042-7158.1996.tb05870.x
- Haynes Richard, From Artemisinin to New Artemisinin Antimalarials: Biosynthesis, Extraction, Old and New Derivatives, Stereochemistry and Medicinal Chemistry Requirements, 10.2174/156802606776743129
- Haynes Richard K., Chan Ho-Wai, Lung Chung-Man, Ng Nga-Chun, Wong Ho-Ning, Shek Lai Yung, Williams Ian D., Cartwright Anthony, Gomes Melba F., Artesunate and Dihydroartemisinin (DHA): Unusual Decomposition Products Formed under Mild Conditions and Comments on the Fitness of DHA as an Antimalarial Drug, 10.1002/cmdc.200700064
- Jansen F., Soomro Shahid, Chemical Instability Determines the Biological Action of the Artemisinins, 10.2174/092986707782793844
- Schuirmann Donald J., A comparison of the Two One-Sided Tests Procedure and the Power Approach for assessing the equivalence of average bioavailability, 10.1007/bf01068419
- Navaratnam Visweswaran, Ramanathan Surash, Wahab Mohd Suhaimi Ab., Siew Hua Gan, Mansor Sharif Mahsufi, Kiechel Jean-René, Vaillant Michel, Taylor Walter R. J., Olliaro Piero, Tolerability and pharmacokinetics of non-fixed and fixed combinations of artesunate and amodiaquine in Malaysian healthy normal volunteers, 10.1007/s00228-009-0656-1
- Batty Kevin T., Anh Thu Le Thi, Davis Timothy M. E., Ilett Kenneth F., Xuan Mai Truong, Canh Hung Nguyen, Phuc Tien Nguyen, Powell Shane M., Van Thien Huynh, Quang Binh Tran, Kim Nguyen Van, A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria : Pharmacokinetics of artesunate in falciparum malaria, 10.1046/j.1365-2125.1998.00655.x
- Khanh NX, de Vries PJ, Ha LD, van Boxtel CJ, Koopmans R, Kager PA (1999) Declining concentrations of dihydroartemisinin in plasma during 5-day oral treatment with artesunate for Falciparum malaria. Antimicrob Agents Chemother 43:690–692
- Newton P. N., van Vugt M., Teja-Isavadharm P., Siriyanonda D., Rasameesoroj M., Teerapong P., Ruangveerayuth R., Slight T., Nosten F., Suputtamongkol Y., Looareesuwan S., White N. J., Comparison of Oral Artesunate and Dihydroartemisinin Antimalarial Bioavailabilities in Acute Falciparum Malaria, 10.1128/aac.46.4.1125-1127.2002
- EMEA/CHMP/EWP (2006) Questions & answers on the bioavailability and bioequivalence guideline. EMEA/CHMP/EWP, London
- Churchill Frederick C., Patchen Leslie C., C. Campbell Carlos, Schwartz Ira K., Nguyen-Dinh Phuc, Dickinson Charlotte M., Amodiaquine as a prodrug: Importance of metabolite(s) in the antimalarial effect of amodiaquine in humans, 10.1016/0024-3205(85)90285-1
- Aweeka Francesca T, German Polina I, Clinical Pharmacology of Artemisinin-Based Combination Therapies : , 10.2165/00003088-200847020-00002
- Orrell Catherine, Little Francesca, Smith Peter, Folb Peter, Taylor Walter, Olliaro Piero, Barnes Karen I., Pharmacokinetics and tolerability of artesunate and amodiaquine alone and in combination in healthy volunteers, 10.1007/s00228-007-0452-8
- Stepniewska Kasia, Taylor Walter, Sirima Sodiomon B, Ouedraogo Esperance B, Ouedraogo Alphonse, Gansané Adama, Simpson Julie A, Morgan Caroline C, White Nicholas J, Kiechel Jean-René, Population pharmacokinetics of artesunate and amodiaquine in African children, 10.1186/1475-2875-8-200
- White Nicholas J., Antimalarial drug resistance, 10.1172/jci21682
- White NJ (1997) Assessment of the pharmacodynamic properties of antimalarial drugs in vivo. Antimicrob Agents Chemother 41:1413–1422
- White N. J., Qinghaosu (Artemisinin): The Price of Success, 10.1126/science.1155165
Bibliographic reference |
Fortin, Anny ; Verbeeck, Roger-K. ; Jansen, Frans H.. Comparative oral bioavailability of non-fixed and fixed combinations of artesunate and amodiaquine in healthy Indian male volunteers. In: European Journal of Clinical Pharmacology, Vol. 67, no. 3, p. 267-275 (2011) |
Permanent URL |
http://hdl.handle.net/2078.1/105963 |